Evidence map›Paper›PMID 37966706›Full record

ArticleAnnals of surgical oncology2024

Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.

Caroline A Gjorup, Rachel Woodford, Isabel Li, Matteo S Carlino, Sydney Ch'ng, David Chung, Edward Hsiao, Serigne N Lo, Kevin London, Georgina V Long and 12 more

Open access · hybridAbstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it

0cells of the map it votes in

7citing papers in PubMed

2.5field-weighted citation impact, top 9% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

Is Ultrasound-Based Imaging Essential for Melanoma Active Surveillance?Annals of surgical oncology · 2026
Article
ASO Author Reflections: Reevaluating the Role of Nodal Basin Ultrasound in Melanoma Active Surveillance.Annals of surgical oncology · 2026
Article
Optimal Follow-Up of Sentinel Node Positive Melanoma Patients?Annals of surgical oncology · 2026
Article
Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients with Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial.Annals of surgical oncology · 2026
Article
Oncoplastic surgery for cutaneous head and neck cancers: A novel technique combining wide excision, local flap reconstruction and sentinel node biopsy.JPRAS open · 2025
Article
Annals of Surgical Oncology Practice Guidelines Series: Adjuvant and Neoadjuvant Therapy for Melanoma.Annals of surgical oncology · 2025
Review
Management of Localized Melanoma in the Anti-PD-1 Era.Current oncology reports · 2024
Review

4 · The record

Corrections and comments

Commented on by
ASO Author Reflections: Recurrence in Sentinel Node-Positive Node Fields in Melanoma Patients Undergoing Surveillance Is More Common outside the Node Field.2024

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 2 countries.

Caroline A GjorupMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Rachel WoodfordMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Isabel LiMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Matteo S CarlinoMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Sydney Ch'ngMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

David ChungFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.

Edward HsiaoMater Imaging, Mater Hospital, North Sydney, Australia.

Serigne N LoMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Kevin LondonFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.

Georgina V LongMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Alexander M MenziesMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Omgo E NiewegMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Thomas E PenningtonMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Michael A RtshiladzeMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Robyn P M SawMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Richard A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Kerwin F ShannonMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Andrew J SpillaneMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Jonathan R StretchMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

John F ThompsonMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Alexander H R VareyMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.

Alexander C J van AkkooiMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia. alexander.vanakkooi@melanoma.org.au.ORCID http://orcid.org/0000-0002-3262-6935

The University of Sydney · AUMater Health Services · AURoyal Prince Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn sentinel node-positive (SN+ve) melanoma patients, active surveillance with regular ultrasound examination of the node field has become standard, rather than completion lymph node dissection (CLND). A proportion of these patients now receive adjuvant systemic therapy and have routine cross-sectional imaging (computed tomography [CT] or positron emission tomography [PET]/CT). The role of concurrent ultrasound (US) surveillance in these patients is unclear. The purpose of our study was to describe the modality of detection of nodal recurrence in SN+ve node fields.

methodsSN+ve melanoma patients who did not undergo CLND treated at a single institution from January 1, 2016 to December 31, 2020 were included.

resultsA total of 225 SN+ve patients with a median follow-up of 23 months were included. Of these, 119 (53%) received adjuvant systemic therapy. Eighty (36%) developed a recurrence at any site; 24 (11%) recurred first in the SN+ve field, of which 12 (5%) were confirmed node field recurrence only at 2 months follow-up. The nodal recurrences were first detected by ultrasound in seven (3%), CT in seven (3%), and PET/CT in seven (3%) patients. All nodal recurrences evident on US were also evident on PET/CT and vice versa.

conclusionsThe high rate of recurrences outside the node field and the identification of all US-detected nodal recurrences on concurrent cross-sectional imaging modalities suggest that routine concurrent ultrasound surveillance of the node-positive field may be unnecessary for SN+ve melanoma patients having routine cross-sectional imaging.

Indexed as

MelanomaSentinel Lymph NodeSkin NeoplasmsAdjuvants, ImmunologicHumansLymph Node ExcisionPositron Emission Tomography Computed TomographyRetrospective StudiesSentinel Lymph Node BiopsyAdjuvants, ImmunologicAdjuvant therapyCTDiagnosisImagingMelanomaNodalPET/CTRecurrenceSentinel lymph node biopsy (SLNB)Sentinel lymph node (SLN)Sentinel node (SN)Stage IIISurveillanceUltrasound

Identifiers

PMID37966706

DOI10.1038/s41379-020-0500-9

PMCPMC10838221

OpenAlexW4388697489

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.